Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
read more >
Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
read more >
Biotech Stocks Break Out
Source: Ron Struthers (03/19/2024)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
read more >
Is This Pharma Set To Break Out After COPD Drug Approval?
Source: Streetwise Reports (03/15/2024)
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.
read more >
This Biotech Is a Potential Disruptor, Expert Says
Source: Chris Temple (03/12/2024)
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.
read more >